Fig 1. A randomized study in patients with relapsed or refractory, CD22-positive, Philadelphia chromosome–positive or Philadelphia chromosome–negative acute lymphoblastic leukemia: inotuzumab ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results